Phase 3 Lung Cancer Metastatic Clinical Trials
4 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–4 of 4 trials
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer MetastaticNon-Small-Cell Lung CarcinomaNon-small Cell Carcinoma
Pfizer680 enrolled305 locationsNCT07144280
Recruiting
Phase 3
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Triple-Negative Breast CancerCervical CancerUrothelial Carcinoma+12 more
UNICANCER646 enrolled40 locationsNCT05078047
Recruiting
Phase 3
Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC
Non-small Cell Lung Cancer Metastatic
Laboratorio Elea Phoenix S.A.174 enrolled1 locationNCT05668650
Recruiting
Phase 3
Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
Non-small Cell Lung Cancer Metastatic
Shanghai Cancer Hospital, China300 enrolled1 locationNCT05800223